| dc.contributor.author | Messinger, D. | |
| dc.contributor.author | Besisik, F. | |
| dc.contributor.author | Samuel, D. | |
| dc.contributor.author | Junker, H. | |
| dc.contributor.author | Cheinquer, H. | |
| dc.contributor.author | Peck-Radosavljevic, M. | |
| dc.contributor.author | Boletis, J. | |
| dc.contributor.author | Ferraz, M. Lucia | |
| dc.contributor.author | Alric, L. | |
| dc.date.accessioned | 2021-03-03T11:50:12Z | |
| dc.date.available | 2021-03-03T11:50:12Z | |
| dc.identifier.citation | Peck-Radosavljevic M., Boletis J., Besisik F., Ferraz M. L. , Alric L., Samuel D., Messinger D., Junker H., Cheinquer H., "Use of low-dose peginterferon alpha-2a (40kD) 628 (pegasys (R)) to treat hepatitis C-infected end-stage renal disease patients undergoing haemodialysis: Interim results from a randomised study", 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Barcelona, İspanya, 11 - 15 Nisan 2007, cilt.46 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_2a4a512c-8e1b-48fb-998a-5b573f78531c | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/33216 | |
| dc.identifier.uri | https://doi.org/10.1016/s0168-8278(07)62226-0 | |
| dc.language.iso | eng | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Gastroenteroloji-(Hepatoloji) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
| dc.title | Use of low-dose peginterferon alpha-2a (40kD) 628 (pegasys (R)) to treat hepatitis C-infected end-stage renal disease patients undergoing haemodialysis: Interim results from a randomised study | |
| dc.type | Bildiri | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 46 | |
| dc.contributor.firstauthorID | 133619 | |
